Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis

  title={Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis},
  author={Elijah L. Carlson and Vengadeshprabhu Karuppagounder and William J. Pinamont and Natalie K. Yoshioka and Adeel Ahmad and Eric M. Schott and Heather K. Le Bleu and Michael J. Zuscik and Reyad A. Elbarbary and Fadia Kamal},
  journal={Science Translational Medicine},
G protein–coupled receptor kinase 2 is increased in OA, and inhibition by the antidepressant paroxetine prevents disease progression. An antidepressant for arthritis? Pathological chondrocyte hypertrophy contributes to osteoarthritis (OA), a degenerative disease of the cartilage and bone. Carlson et al. studied the role of G protein–coupled receptor kinase 2 (GRK2), which is linked to cardiac hypertrophy, in OA. GRK2 was elevated in chondrocytes in mouse models of OA and in injured human… 
G Protein-Coupled Receptors in Osteoarthritis
Examples of GPCRs which may offer attractive therapeutic strategies for OA, including receptors for cannabinoids, hormones, prostaglandins, fatty acids, adenosines, chemokines, and the main challenges for developing these therapies are discussed.
Antidepressant identified as potential DMOAD
  • J. McHugh
  • Medicine, Biology
    Nature Reviews Rheumatology
  • 2021
In a surgical model of osteoarthritis (OA), chondrocyte-specific deletion of GRK2, or pharmacological inhibition with the repurposed FDA-approved antidepressant drug paroxetine, attenuated chondROcyte hypertrophy, matrix degradation and OA progression.
A novel prostaglandin E receptor 4 (EP4) small molecule antagonist induces articular cartilage regeneration
It is demonstrated that EP4 can act as a promising therapeutic target for cartilage regeneration and the novel EP4 antagonist HL-43 has the clinical potential to be used for carticular cartilage repair and regeneration.
Resolvin D1‐loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis
The Lipo‐RvD1 formulation was able to target and suppress the formation of the osteophytes and showed analgesic effect, thus emphasizing its ability to treat clinical symptoms of OA and could represent a patient‐compliant treatment for OA.
Structural changes in the collagen network of joint tissues in late stages of murine OA
These findings provide comprehensive insights into the microarchitectural changes of extracellular matrix in OA and serve as guidelines for studies investigating therapies that target collagenous changes as means to impede the progression of osteoarthritis.
Early Gβγ-GRK2 Inhibition Ameliorates Osteoarthritis Development by Simultaneous Anti-Inflammatory and Chondroprotective Effects
It is shown that early Gβγ-GRK2 inhibition is of higher therapeutic efficacy in OA than delayed inhibition, as it prevents OA development by inhibiting the early inflammatory response.
Pharmacologic inhibition of EPHA2 decreases inflammation and pathological endochondral ossification in osteoarthritis
It is demonstrated that pharmacological inhibition of EPHA2 with ALW-II-41-27 is a promising disease-modifying treatment that paves the route for a novel drug discovery pipeline for osteoarthritis.


Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology
This study clearly demonstrates PAR2 plays a critical role, via chondrocytes, in osteophyte development and subchondral bone changes, which occur prior to PAR2-mediated cartilage damage, which likely occurs independently of OA-related bone changes.
Fluoxetine ameliorates cartilage degradation in osteoarthritis by inhibiting Wnt/β-catenin signaling
Fluoxetine, an antidepressant in the class of selective serotonin reuptake inhibitors (SSRI), down-regulated Wnt/β-catenin signaling in human chondrosarcoma cells and suppressed LiCl-induced β- catenin accumulation in human OA chondrocytes.
Emerging drugs for the treatment of knee osteoarthritis
Given the complexity of OA, one single therapy is unlikely to be universally and uniformly effective, and promising therapies are under development, but there are obstacles in the translation of treatment from preclinical models and trial designs need to be cognizant of the complex reasons for previous trial failures.
Small molecule disruption of G protein βγ subunit signaling reprograms human macrophage phenotype and prevents autoimmune myocarditis in rats
The data suggest that the small molecule Gβγ inhibitor, gallein, could be an important pharmacologic therapy for HF as it can switch the phenotypic reprogramming from M1 to M2 phenotype in a rat model of EAM heart and in human macrophages.
Serotonin 5HT2A receptor antagonism mediated anti-inflammatory and anti-fibrotic effect in adriamycin-induced CKD in rats
  • G. KaurP. Krishan
  • Biology, Medicine
    Naunyn-Schmiedeberg's Archives of Pharmacology
  • 2020
Ketanserin reduces renal fibrosis and inflammation in adriamycin-induced chronic kidney disease by suppressing 5-HT2A, IL-6, TGF-β and collagen IV expression in renal tissue.
Paroxetine alleviates T lymphocyte activation and infiltration to joints of collagen-induced arthritis
This study elucidates that paroxetine attenuates the symptoms of CIA rats due to its inhibitory effect on T cell activation and infiltration to synovial tissue via suppression of ERK pathway.
Identification of the calcitonin receptor in osteoarthritic chondrocytes
Human OA articular cartilage chondrocytes do indeed express the CTR, which makes the articular a pharmacological target of salmon calcitonin.